Presbia Priced, Nasdaq: LENS

Sells surgically implanted lenses to correct age-related vision loss.

Industry: Health Care

Latest Trade: $3.18 0.00 (0.0%)

First Day Return: -18.5%

Return from IPO: -68.2%

Industry: Health Care

Presbia PLC is an ophthalmic device company which has developed, and is currently marketing, a proprietary optical lens implant for treating presbyopia. Presbyopia is the age related loss of near field vision. It is the condition that requires many adults to require reading glasses. Our Flexivue microlens is a miniature lens designed to be surgically implanted in the cornea of the patient’s non-dominant eye. Through a process called “neural adaptation,” the patient’s brain rapidly adapts to use the dominant eye for distance, and the microlens assisted non-dominant eye for near vision. The procedure is fast, non-invasive, and can be reversed or updated if necessary. We have commercialized the Flexivue microlens in certain strategic countries where we currently have marketing approval. Our goal is to become a leading provider of corneal inlay presbyopia-correcting treatment worldwide.
more less
IPO News for Presbia
more
IPO Data
IPO File Date 03/20/2014
Offer Price $10.00
Price Range $11.00 - $13.00
Offer Shares (mm) 4.2
Deal Size ($mm) $42
IPO Data
IPO Date 01/28/2015
Offer Price $10.00
Price Range $11.00 - $13.00
Offer Shares (mm) 4.2
Deal Size ($mm) $42
Underwriters
more
Company Data
Headquarters Dublin, Ireland
Founded 2007
Employees 33
Website www.presbia.com